Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2007

Guida Teresa, Anaganti Suresh, Provitera Livia, Gedrich Richard, Sullivan Elizabeth, Wilhelm Scott M, Santoro Massimo, Carlomagno Francesca

Abstract excerpt

PURPOSE: Targeting of KIT and platelet-derived growth factor receptor (PDGFR) tyrosine kinases by imatinib is an effective anticancer strategy. However, mutations of the gatekeeper residue (T670 in KIT and T681 in PDGFRbeta) render the two kinases resistant to imatinib. The aim of this study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Interleukin-3

Share to Niacinamide

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins c-sis

Share to Sorafenib

Source

Identifiers

PMID: 17545544
DOI: 10.1158/1078-0432.CCR-06-2667

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17545544-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.PMID 17545544Read ↗

Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.Semantic proximity Read ↗

Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.Semantic proximity Read ↗

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.Semantic proximity Read ↗

A precision therapy against cancers driven by KIT/PDGFRA mutations.Semantic proximity Read ↗

Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsSemantic proximity Read ↗

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.Semantic proximity Read ↗

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.Semantic proximity Read ↗

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.Semantic proximity Read ↗

Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors.Semantic proximity Read ↗

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.Semantic proximity Read ↗

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.Semantic proximity Read ↗

Preliminary in vitro and in vivo investigation of a potent platelet derived growth factor receptor (PDGFR) family kinase inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.